Paul-Peter Tak

Last updated

Paul Peter Tak
FMedSci
Alma mater Vrije Universiteit Amsterdam
Leiden University
Scientific career
FieldsImmunology, gene therapy, bioelectronics
InstitutionsCandel Therapeutics
Kintai Therapeutics
GlaxoSmithKline

Paul-Peter Tak is a Dutch immunologist and academic specialising in the fields of internal medicine, rheumatology and immunology. Tak has been the President & CEO of Candel Therapeutics since September 2020.

Contents

Life and career

Tak graduated with a medical degree cum laude from the Amsterdam University Medical Centers and began his medical career as a practitioner in the Bronovo Hospital, The Hague. He joined Leiden University Medical Centre as a Fellow in Internal Medicine in 1990 and was awarded a Fellowship in Rheumatology in 1995. Tak received his PhD from Leiden University in 1996 for his thesis Immunohistologic studies of rheumatoid synovial tissue. He worked as a Clinical Associate Professor of Medicine at the University of California, San Diego, and next served as Professor of Medicine and Chair of the Department of Clinical Immunology & Rheumatology at Amsterdam UMC. [1]

Tak has studied the role of the vagus nerve in chronic inflammation, work which provided the basis for clinical trials exploring bioelectronics as a novel therapeutic approach in rheumatoid arthritis patients. He is also known for his studies on synovial biopsy and synovial tissue analysis. In his academic life, Tak has been Visiting Professor, William Harvey Research Institute (London), Honorary Senior Visiting Fellow (University of Cambridge), Honorary Professor of Rheumatology (Ghent University) and was elected a Fellow of the Academy of Medical Sciences (U.K.) in 2016. [2] [3] [4]

He was elected by peers as "Best Rheumatologist" in the Netherlands in 2011, and received the Medal of Honour of the Netherlands Society for Rheumatology the same year. He was rated as one of the world’s top 3 doctors in the field of rheumatoid arthritis by Expertscape in 2014. [5] [6] [7]

From 2011 to 2018, Tak worked at GlaxoSmithKline as Senior Vice President, Chief Immunology Officer and Global Development Leader. He was also the Chair of the Scientific Review Board. In 2018, Tak cofounded Sitryx Therapeutics with researchers Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum. Tak was appointed as Board Director of Levicept in July 2018. Tak was chief executive at Tempero Pharmaceutical, which was acquired by GlaxoSmithKline, then served as Chief Executive Officer at Kintai Therapeutics in 2018. He was also a venture partner at Flagship Pioneering. In September 2020, Tak became president and CEO of Candel Therapeutics and, in July of the following year, led the company to an Initial Public Offering (IPO) on the Nasdaq. In 2021, Tak was named as one of the most inspiring people in life sciences on the PharmaVOICE100 list. Tak was included in The Medicine Maker Power List 2023 as one of the top ten leaders in the Biopharmaceuticals category. In March 2023, Tak was appointed Chair of the Board of Directors at Citryll. [8] [9] [10] [11]

Publications

Tak has an h-index of 144 according to Google Scholar. [12] His publications include:

Related Research Articles

<span class="mw-page-title-main">Rheumatoid arthritis</span> Type of autoimmune arthritis

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body, including skin, eyes, lungs, heart, nerves, and blood. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.

<span class="mw-page-title-main">GSK plc</span> UK healthcare company

GSK plc is a British multinational pharmaceutical and biotechnology company with headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

Rheumatology is a branch of medicine devoted to the diagnosis and management of disorders whose common feature is inflammation in the bones, muscles, joints, and internal organs. Rheumatology covers more than 100 different complex diseases, collectively known as rheumatic diseases, which includes many forms of arthritis as well as lupus and Sjögren's syndrome. Doctors who have undergone formal training in rheumatology are called rheumatologists.

<span class="mw-page-title-main">Rheumatism</span> Medical conditions affecting the joints or connective tissue

Rheumatism or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue. Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and "non-articular rheumatism", also known as "regional pain syndrome" or "soft tissue rheumatism". There is a close overlap between the term soft tissue disorder and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions.

<span class="mw-page-title-main">Belimumab</span> Pharmaceutical drug

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.

Allen Caruthers Steere is an American rheumatologist. He is a professor of rheumatology at Harvard University and previously at Tufts University and Yale University. Steere and his mentor, Stephen Malawista of Yale University, are credited with discovering and naming Lyme disease, and he has published almost 300 scholarly articles on Lyme disease during his more than 40 years of studies of this infection. At a ceremony in Hartford, Connecticut in 1998, Governor John G. Rowland declared September 24 to be "Allen C. Steere Day".

<span class="mw-page-title-main">Rheumatoid nodule</span> Medical condition

A rheumatoid nodule is a lump of tissue, or an area of swelling, that appears on the exterior of the skin usually around the olecranon or the interphalangeal joints, but can appear in other areas. There are four different types of rheumatoid nodules: subcutaneous rheumatoid nodules, cardiac nodules, pulmonary nodules, and central nervous systems nodules. These nodules occur almost exclusively in association with rheumatoid arthritis. Very rarely do rheumatoid nodules occur as rheumatoid nodulosis in the absence of rheumatoid arthritis. Rheumatoid nodules can also appear in areas of the body other than the skin. Less commonly they occur in the lining of the lungs or other internal organs. The occurrence of nodules in the lungs of miners exposed to silica dust was known as Caplan’s syndrome. Rarely, the nodules occur at diverse sites on body.

<span class="mw-page-title-main">Kevin J. Tracey</span>

Kevin J. Tracey, a neurosurgeon and inventor, is the president and CEO of the Feinstein Institute for Medical Research, professor of neurosurgery and molecular medicine at the Zucker School of Medicine, and president of the Elmezzi Graduate School of Molecular Medicine in Manhasset, New York. The Public Library of Science Magazine, PLOS Biology, recognized Tracey in 2019 as one of the most cited researchers in the world.

<span class="mw-page-title-main">Darapladib</span> Chemical compound

Darapladib is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis.

Sir Marc Feldmann, is an Australian-educated British immunologist. He is a professor at the University of Oxford and a senior research fellow at Somerville College, Oxford.

<span class="mw-page-title-main">Losmapimod</span> Chemical compound

Losmapimod (GW856553X) is an investigational drug that reached stage III clinical trials for multiple medical conditions, but did not prove efficacy. It was most recently in development by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Losmapimod selectively inhibits enzymes p38α/β mitogen-activated protein kinases (MAPKs), which are modulators of DUX4 expression and mediators of inflammation.

<span class="mw-page-title-main">Intepirdine</span> Chemical compound

Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.

Sirukumab is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6 (IL-6).

Hal V. Barron is an American clinician-scientist and drug developer who served as president of research and development at GlaxoSmithKline from March 2018 until 2022, when he resigned in order to join the cellular reprogramming venture Altos Labs in August of that year. Prior to this he served as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.

<span class="mw-page-title-main">Gary Firestein</span> American rheumatologist

Gary S. Firestein is an American rheumatologist, professor, and founding director of the Altman Clinical and Translational Research Institute (ACTRI) at the University of California San Diego and Senior Associate Vice Chancellor for Health Sciences at University of California, San Diego.

<span class="mw-page-title-main">Moncef Slaoui</span> Moroccan-American-Belgian doctor and researcher

Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.

<span class="mw-page-title-main">Oscar Segurado</span> American immunologist

Oscar Segurado is a medical researcher and academician. He holds a tenured professorship of Immunology at the University of León, Spain. Segurado has conducted research in the domains of Rheumatology and Immunology. His scientific work focuses on Rheumatoid arthritis.

Fionula Brennan (1957–2012) was an Irish immunologist and Professor of Cytokine Immunopathology at the Kennedy Institute of Rheumatology.

Paul Emery is a British rheumatologist, researcher, and academic. Emery has been the Versus Arthritis Professor of Rheumatology at the University of Leeds from 1995 to 2017, Head of its Rheumatology Department from 1995 to 2008. He is Head of the Academic Unit of Musculoskeletal Disease and Lead Clinician of Rheumatology at the Leeds Teaching Hospital NHS Trust, and was the Director of the NIHR Leeds Biomedical Research Centre from 2009 to 2022. He is known for introducing early intervention in inflammatory arthritis. Emery played a critical role in bringing sensitive imaging (MRI) into rheumatology practice. In 2012, Emery was awarded the Carol Nachman Prize for Rheumatology, and as of 2024, he has published over 1660 peer-reviewed articles with over 160,000 citations. Emery was the most cited European/World Rheumatologist in 2010-2020, and was selected in the European Journal of Clinical Investigation's "list of highly influential biomedical researchers, 1996–2020."

Iain Blair McInnes is a Scottish rheumatologist, Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow. His research has focused on inflammatory diseases, particularly rheumatoid arthritis and psoriatic arthritis.

References

  1. ↑ "Paul Peter Tak | Precision Medicine". www.terrapinn.com. 17 May 2018. Retrieved 3 August 2018.
  2. ↑ Tak, Professor Paul-Peter (December 2017). "Interview with Paul-Peter Tak: Stimulating the vagus nerve to treat rheumatoid arthritis". Bioelectronics in Medicine. 1 (1): 17–20. doi: 10.2217/bem-2017-0012 . ISSN   2059-1500.
  3. ↑ "ACR Annual Meeting" (PDF). American College of Rheumatology. November 2012. Retrieved 7 August 2018.
  4. ↑ "Professor Paul-Peter Tak | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 8 August 2018.
  5. ↑ "Mednet Topartsen 2010". Mednet (in Dutch). 4 (1): 6–15. January 2011. doi:10.1007/s12462-011-0006-8. ISSN   1568-7716. S2CID   195312669.
  6. ↑ "Prizes". NVR Nederlandse Vereniging voor Reumatologie (in Dutch). Retrieved 10 August 2018.
  7. ↑ Expertscape. "Expertscape Ranks World's Top Doctors and Hospitals in Rheumatoid Arthritis". PRLog. Retrieved 10 August 2018.
  8. ↑ Eaton, Elizabeth. "Tak leaves GSK to join Flagship". Biocentury.com. Retrieved 31 January 2019.
  9. ↑ "GlaxoSmithKline Scientist Steps Down to Join Flagship Pioneering". Business Leader. 7 February 2019. Retrieved 8 February 2019.
  10. ↑ "Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline". FierceBiotech. 9 December 2020. Retrieved 17 March 2021.
  11. ↑ Al Idrus, Amirah. "Ex-GSK Shingrix chief Pfefer lands at Flagship as its 2nd CEO-Partner". FierceBiotech. Retrieved 30 October 2020.
  12. ↑ "Paul Peter Tak". Google Scholar . Retrieved 27 September 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.